Anthem Biosciences

Anthem Biosciences

696.60
-5.65
(-0.80%)
hide
Key Fundamentals
Add Ratio
Market Cap
39,439.10 Cr
EPS
8.07
PE Ratio
86.62
Dividend Yield
0.00 %
Industry
-
52 Week High
873.50
52 Week Low
690.50
PB Ratio
16.23
Debt to Equity
0.08
Sector
-
Analyst Rating and Forecast
- By Refinitiv from2 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+50.00 %
+50.00 %
Hold
Hold+50.00 %
+50.00 %
Sell
Sell0.0 %
0.0 %
Forecast For
Actual

Company News

View All News
Caret
negative
Anthem Biosciences Limited disclosed that a designated person violated the company's Code of Conduct by trading in company securities during a trading window closure period. The violation relates to provisions under SEBI Prohibition of Insider Trading Regulations. The matter will be presented to the upcoming Audit Committee meeting, and the company will provide detailed disclosure and action taken in due course.
neutral
Three companies will see their share lock-in periods expire on Wednesday, October 15. Anthem BioSciences will have 8.9 million shares (2% of outstanding equity) become eligible for trading, with the stock gaining 8% since listing in July at ₹570 per share. Shringar House of Mangalsutra will see 3.6 million shares (4% of outstanding equity) become tradeable, with the stock currently trading around its listing price of ₹188.50. The company's ₹400 crore IPO was oversubscribed by 60 times. Dev Accelerator will have 5.2 million shares (6% of outstanding equity) eligible for trading, though the stock has declined 21% from its IPO price since listing in September. The end of lock-in periods makes shares eligible for trading but does not guarantee they will be sold in the open market.
positive
Anthem Biosciences shares have gained 46% since listing on July 21, with an 11% increase following strong June-quarter results announced on August 13. The drug discovery and manufacturing services company reported revenue growth of 59.5% year-on-year to ₹540.2 crore and net profit surge of 64.8% to ₹135.8 crore in the June quarter. The company is expanding capacity by 155 kilolitres to reach 425 kilolitres total by September 2025, with 54 kilolitres added in the June quarter. Two products received approval, increasing the commercial portfolio from 10 to 12. The company expects 20% annual revenue growth for FY26. Operating margin dropped to 38.1% from 39.2% due to share-based compensation charges of ₹4.4 crore. Anthem completed backward integration on a key molecule and is developing GLP-1 obesity and diabetes drugs as patents expire in multiple markets.
View more

Automatic Screeners on ScanX

Growth Rate
Revenue Growth
30.15 %
Net Income Growth
22.87 %
Cash Flow Change
198.49 %
ROE
-1.83 %
ROCE
13.75 %
EBITDA Margin (Avg.)
2.22 %

Quarterly Financial Results

Quarterly Financials
Jun 2024
Mar 2025
Jun 2025
Revenue
358
497
563
Expenses
218
288
349
EBITDA
140
209
214
Operating Profit %
36 %
40 %
35 %
Depreciation
19
30
27
Interest
4
1
2
Profit Before Tax
118
178
186
Tax
36
96
51
Net Profit
82
83
136
EPS in ₹
1.47
1.48
2.43

Balance Sheet

Balance Sheet
2020
2021
2022
2023
2024
2025
Total Assets
787
1,034
1,619
2,015
2,398
2,808
Fixed Assets
306
361
329
449
483
705
Current Assets
403
616
1,098
1,323
1,482
1,737
Capital Work in Progress
50
19
154
164
345
297
Investments
99
209
273
499
472
433
Other Assets
333
445
863
903
1,099
1,373
Total Liabilities
787
1,034
1,619
2,015
2,398
2,808
Current Liabilities
247
285
223
164
339
326
Non Current Liabilities
118
47
41
110
135
72
Total Equity
422
702
1,355
1,741
1,925
2,410
Reserve & Surplus
414
693
1,346
1,627
1,813
2,298
Share Capital
8
9
9
114
112
112

Cash Flow

Cash Flow
2020
2021
2022
2023
2024
2025
Net Cash Flow
9
18
308
-6
-159
133
Investing Activities
-109
-196
-205
-376
-222
-152
Operating Activities
166
278
333
306
140
418
Financing Activities
-48
-63
181
64
-77
-134

Share Holding

% Holding
Dec 2024
Jul 2025
Sept 2025
Promoter
77.23 %
76.88 %
74.69 %
FIIs
0.00 %
0.00 %
1.67 %
DIIs
0.00 %
0.00 %
7.22 %
Government
0.00 %
0.00 %
0.00 %
Public / Retail
0.00 %
0.00 %
9.61 %
Others
22.77 %
23.12 %
6.81 %
No of Share Holders
16
761
2,17,681

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
08 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
08 Nov 2025 742.15 702.50
13 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
13 Aug 2025 749.65 743.45

Announcements

Intimation Of Violation Under CompanyS Code Of Conduct To Regulate Monitor And Report Trading By Designated Persons As Required Under SEBI (Prohibition Of Insider Trading) Regulations 2015 (SEBI PIT Regulations)9 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 23, 2025
Board Meeting Intimation for The Financial Results For Quarter And Half Year Ended September 30 2025Oct 23, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 06, 2025
Closure of Trading WindowSep 29, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 19, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportSep 15, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 18, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 14, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 14, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 14, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotAug 13, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationAug 13, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 13, 2025
Outcome Of Board Meeting Held On Wednesday August 13 2025Aug 13, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On Wednesday August 13 2025Aug 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 08, 2025
Board Meeting Intimation for Considering And Approval Of The Unaudited Financial Results For The Quarter Ended June 30 2025Aug 08, 2025
Intimation Under Regulation 30(5) Of The Securities And Exchange Board Of India (Listing Obligation And Disclosures Requirements) Regulation 2015Jul 21, 2025
Announcement Under Regulation 7(1) Of The Securities And Exchange Board Of India (Listing Obligation And Disclosures Requirements) Regulation 2015Jul 21, 2025
Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations 2015Jul 21, 2025
Closure of Trading WindowJul 21, 2025
Appointment of Company Secretary and Compliance OfficerJul 21, 2025
Listing of Equity Shares of Anthem Biosciences LtdJul 21, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Quant Small Cap Fund Direct Plan-Growth
0.00%
-3682926
-0.96%
-1.05%
Kotak Small Cap Fund Direct-Growth
0.00%
-2226066
-0.97%
-1.04%
HSBC Midcap Fund Direct-Growth
0.00%
-2111545
-1.35%
-1.47%
Quant Mid Cap Fund Direct-Growth
0.00%
-1683389
-1.55%
-1.66%
SBI MNC Direct Plan-Growth
0.00%
-1600000
-2.07%
-2.18%
Axis ELSS Tax Saver Direct Plan-Growth
0.00%
-1440566
-0.32%
-0.31%
HDFC Manufacturing Fund Direct - Growth
0.00%
-1400000
-0.92%
-0.92%
Quant Momentum Fund Direct - Growth
0.00%
-1351053
-6.85%
-7.21%
HDFC Business Cycle Fund Direct - Growth
0.00%
-1335040
-3.50%
-3.78%
SBI Healthcare Opportunities Fund Direct Plan-Growth
0.00%
-1200000
-2.32%
-2.48%
Nippon India Pharma Fund Direct-Growth
0.00%
-1058503
-0.99%
-1.04%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth
0.00%
-1052636
-1.29%
-1.40%
Mahindra Manulife Mid Cap Fund Direct - Growth
0.00%
-1007065
-1.92%
-1.30%
PGIM India Midcap Fund Direct-Growth
0.00%
-919299
-0.62%
-0.66%
HDFC Pharma And Healthcare Fund Direct - Growth
0.00%
-810813
-3.26%
-3.47%
Kotak Pioneer Fund Direct - Growth
0.00%
-784030
-1.90%
-2.10%
HSBC Large and Mid Cap Fund Direct - Growth
0.00%
-754472
-1.30%
-1.43%
PGIM India Flexi Cap Fund Direct-Growth
0.00%
-712690
-0.88%
-0.94%
Axis Midcap Direct Plan-Growth
0.00%
-651139
-0.16%
-0.17%
Kotak Large Cap Fund Direct-Growth
0.00%
-612715
-0.45%
-0.49%
Quant Manufacturing Fund Direct - Growth
0.00%
-556316
-5.41%
-5.92%
Quant Large Cap Fund Direct - Growth
0.00%
-526318
-1.48%
-1.62%
Mirae Asset Healthcare Fund Direct - Growth
0.00%
-526318
-1.45%
-1.54%
HDFC ELSS Tax Saver Fund Direct Plan-Growth
0.00%
-494578
-0.23%
-0.24%
Quant Focused Fund Direct-Growth
0.00%
-480000
-3.75%
-4.02%

Technical Indicators

RSI(14)
Neutral
34.05
ATR(14)
Volatile
21.40
STOCH(9,6)
Oversold
10.23
STOCH RSI(14)
Oversold
15.29
MACD(12,26)
Bearish
-2.97
ADX(14)
Strong Trend
27.47
UO(9)
Bearish
37.83
ROC(12)
Downtrend And Accelerating
-9.04
WillR(14)
Oversold
-88.35